Joel Schlessinger, MD
Dermatology · Omaha, NENPI 1720085582
Payments from drug & device makers
Across 1,342 payments — averaging $4108.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.6M
- Novartis$773K
- Pfizer$568K
- Eli Lilly$356K
- Aclaris Therapeutics, Inc.$274K
- Amgen$250K
- plus $1.7M from 28 others
Across 13 payments — averaging $13,865 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nielsen Biosciences, Inc.$145K
- Novartis$30K
- Pfizer$3K
- Eli Lilly$2K
- AbbVie$370
What the payments were for
- Consulting fees$56,28163%
- Speaking & faculty fees$7,4008%
- Travel & lodging$20,19123%
- Food & beverage$5,3286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$43,311
- BOTOX$5,576
- EUCRISA$4,800
- Candin$4,050
- AKLIEF$150
- EPIDUO FORTE$150
- ORACEA$150
- VTAMA$103
How this compares
$5,514,024 in reported general payments places this provider in the 95th percentile of 68 dermatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $70,591 |
| Betamethasone Dipropionate | 83 | $3,747 |
| Fluocinonide | 70 | $3,582 |
| Cephalexin | 384 | $3,225 |
| ValacyclovirValacyclovir Hcl | 55 | $2,521 |
| Minocycline Hcl | 161 | $2,403 |
| Imiquimod | 49 | $2,143 |
| Ketoconazole | 109 | $1,506 |
| Triamcinolone Acetonide | 98 | $1,434 |
| Metronidazole | 28 | $1,348 |
| Fluconazole | 88 | $1,144 |
| Terbinafine Hcl | 162 | $1,107 |
| Mupirocin | 145 | $1,057 |
| Econazole Nitrate | 26 | $752 |
| Rifampin | 13 | $447 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Omaha
- Mathew DaveyOmaha$389K
- Erin BarrettOmaha$144K
- Rachel PersonOmaha$98K
- Sarah LonowskiOmaha$89K
- James ShehanOmaha$51K
- Gage RenschOmaha$11K
- Herschel StollerOmaha$10K
- Deirdre StolmeierOmaha$10K
- Melissa DarlingOmaha$10K
- Christopher HuerterOmaha$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.